Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced ...
SYNTHBODY(TM) introduces a new class of "smart drugs": protein therapeutics with built-in, multi-layered logic gates that actively change how they behave based on what they encounter in the body, a ...
Preclinical data show encouraging activity of azenosertib combinations in ADC-resistant TNBC, supporting the potential for pipeline expansion beyond ovarian cancer Real-world data demonstrate Cyclin ...
The U.S. FDA has granted Fast Track designation for mRNA-4359 in combination with pembrolizumab for the treatment of ...
New AACR data highlight stenoparib’s potential in colorectal cancer through WNT pathway modulationThe Stenoparib-DRP® companion ...
Bria-OTS+ platform provides early, potent and durable activation of innate and adaptive immunity in in-vitro cancer cell line ...
CStone Pharmaceuticals ('CStone,' HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, immunology, inflammation, and other key ...
Akeso, Inc. (9926.HK) ('Akeso' or the 'Company') today announced that positive Phase II results from the COMPASSION-26 study evaluating cadonilimab, its first-in-class PD-1/CTLA-4 bispecific antibody, ...
MedPage Today on MSN
Early Lung Cancer Data Show Why FDA Approved HER2 Agent in First-Line
Zongertinib in phase I trial showed sustained efficacy in aggressive disease ...
Discusses Intracranial Activity of a New Therapy in Small Cell Lung Cancer With Brain Metastases April 20, 2026 8:30 AM ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results